Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Post Transplant Study

This study has been completed.
Sponsor:
Information provided by:
Amgen
ClinicalTrials.gov Identifier:
NCT00395902
First received: November 2, 2006
Last updated: December 20, 2007
Last verified: December 2007
  Purpose

Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients


Condition Intervention
Kidney Tansplant
Secondary Hyperparathyroidism
Hyperparathyroidism
Drug: Sensipar after Post Transplant

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients

Resource links provided by NLM:


Further study details as provided by Amgen:

Estimated Enrollment: 50
Study Start Date: August 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Adults >= 18 years old
  • Subjects who have received Sensipar for a duration of at least 3 months, beginning at least 3 months after a kidney transplant. Subjects must have begun Sensipar teatment no later than Februry 28, 2005 at treating physician's discretion.

Exclusion Criteria:

  • Subjects who received Sensipar before undergoing a kidney transplant
  • Subjects receiving dialysis post-transplant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00395902

Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided

Responsible Party: Global Development Leader, Amgen Inc.
ClinicalTrials.gov Identifier: NCT00395902     History of Changes
Other Study ID Numbers: 20040261, 2004261
Study First Received: November 2, 2006
Last Updated: December 20, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Amgen:
Sensipar
cinacalcet
Mimpara

Additional relevant MeSH terms:
Hyperparathyroidism
Hyperparathyroidism, Secondary
Endocrine System Diseases
Parathyroid Diseases

ClinicalTrials.gov processed this record on November 27, 2014